CTOs on the Move

Neurelis

www.neurelis.com

 
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neurelis.com
  • 11682 El Camino Real Suite 255
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Neurelis raised $114M on 03/10/2021

Similar Companies

Gaia Herbs

Gaia Herbs has established itself as the leading grower and producer of Certified Organic (COG) herbs and herbal products. Gaia Herbs strives to produce pure plant medicines of exceptional quality and purity while enriching the ecology of the earth and the health and harmony of the people that use our phyto-medicines. Gaia Herbs is a certified organic grower and nationally-branded manufacturer of liquid herbal extracts based in Western NC. Find our products at health food retailers and co-ops, natural products retail chains, and healthcare professionals. Our commitment to certified organic herbs ensures strength, purity, and efficacy of our herbal products.

SERVICES Hospital Pharmacy Management and Consulting

SERVICES Hospital Pharmacy Management and Consulting is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ASP Events

Advanced Sterilization Products (ASP) your leaders in sterilization. To protect patients during their most critical moments | Homepage | Irvine CA United States

Unique Pharmaceuticals

Unique Pharmaceuticals is a Temple, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.